Skip to main content
. 2021 Dec 9;8:779282. doi: 10.3389/fcvm.2021.779282

Table 2.

Percentage of high-risk patients by individual markers at baseline in the total population, death, and survival groups.

Markers Threshold (high risk) Percentage in death group n (%) Percentage in survival group n (%) p-value FDR
Cardiac stretch
NT-proBNP >8.0 pg/mL 50 (49.0) 46 (16.6) <0.001 <0.001
Cardiomyocyte injury
Hs-TnT, N (%) >13.3 ng/L 91 (89.2) 186 (66.9) <0.001 <0.001
Inflammation
Hs-CRP >3.7 mg/L 73 (71.6) 152 (54.7) 0.003 0.007
GDF-15 >6.9 ng/mL 29 (28.4) 28 (10.1) <0.001 <0.001
MCP-1 <445.6 pg/mL 47 (46.1) 95 (34.2) 0.034 0.042
TNFα >28.2 pg/mL 70 (68.6) 169 (60.8) 0.161 0.161
sTNFRI >2.17 ng/mL 53 (52.0) 102 (36.7) 0.007 0.013
sTNFRII >14.9 ng/mL 33 (32.4) 54 (19.4) 0.008 0.013
Endothelial function
Endoglin >3.21 ng/mL 46 (45.1) 85 (30.6) 0.008 0.013
Extracellular matrix turnover
TIMP-1 >72.0 ng/mL 99 (97.1) 229 (82.4) <0.001 <0.001
TIMP-2 >44.5 ng/mL 92 (90.2) 222 (79.9) 0.018 0.027
MMP-2 >290.7 ng/mL 39 (38.2) 63 (22.7) 0.002 0.006
MMP-8 <11.8 ng/mL 93 (91.2) 234 (84.2) 0.081 0.085
MMP-9 >133.5 ng/mL 81 (79.4) 180 (64.8) 0.006 0.013
Fibrosis
Galectin-3 >9.26 ng/mL 84 (82.4) 181 (65.1) 0.001 0.004
sST2 >39.1 ng/mL 21 (20.6) 32 (11.5) 0.025 0.032
Renal function
Lipocanlin-2 >289.9 ng/mL 58 (56.9) 126 (45.3) 0.046 0.055
Cystatin-C >1,953 ng/mL 55 (53.9) 121 (43.5) 0.072 0.08
Ascend_HF score >5.0 76 (74.5) 146 (52.5) <0.001 <0.001

NT-proBNP, N-terminal pro B-type brain-type natriuretic peptide; Hs-TNT, high-sensitivity cardiac troponin T; Hs-CRP, high-sensitivity C-reactive protein; GDF-15, growth differentiation factor-15; MCP-1, monocyte chemoattractant protein-1; TNFα, tumor necrosis factor-α; sTNFR, soluble tumor necrosis factor-receptor; TIMP, tissue inhibitor of metalloproteinases; MMP, matrix metalloproteinase; sST2, soluble suppression of tumorigenicity 2; P value <0.05 and FDR <0.05 are shown in bold.